Protecting Consumer Access to Generic Drugs Act of 2009

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.2 - Repealing the Job-Killing Health Care Law Act H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1249/S.23 - America Invents Act H.R.1260/S.515/S.610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 - Life Sciences Jobs and Investment Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Medical Liability Reform Orphan Drugs Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.2 - Repealing the Job-Killing Health Care Law Act H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1249/S.23 - America Invents Act H.R.1260/S.515/S.610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 - Life Sciences Jobs and Investment Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Medical Liability Reform Orphan Drugs Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.2 - Repealing the Job-Killing Health Care Law Act H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1249/S.23 - America Invents Act H.R.1260/S.515/S.610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 - Life Sciences Jobs and Investment Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Medical Liability Reform Orphan Drugs Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.2 - Repealing the Job-Killing Health Care Law Act H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1249/S.23 - America Invents Act H.R.1260/S.515/S.610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 - Life Sciences Jobs and Investment Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Medical Liability Reform Orphan Drugs Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; FDA-PDUFA reauthorization. Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act; Generating Antibiotic Incentives Now (GAIN Act)

Client expense: Not reported · Firm income: $35,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3590 The Patient Protection and Affordable Care Act - General Healh Care Coverage and Reimbursement; implementation issues. H.R. 6331 The Gain Act The Food and Drug Administration legislative and regulatory implementation issues. S.369 Preserve Access to Affordable Generics Act H.R. 1706 Protecting Consumer Access to Generic Drugs Act H.R. 573 and S. 501 Fair Prescription Drug Competition Act; Generating Antibiotic Incentive Now (GAIN Act) Pub. L. 111-148 Patient Protection and Affordable Care Act of 2010 Pub. L. 111-152 Health Care and Education Reconcilliation Act of 2010 Medical Research Antibiotic Resistance Issues Issues relating to antibiotic and antimicrobial resistance

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; FDA-PDUFA reauthorization. Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1204 - Community Pharmacy Fairness Act, Electronic Prescribing, Mail Order and Pharmacy Chronic Care Management H.R. 1706, S369 relating to settlement payments between brand and generic manufacturers, issues related to oversight of pharmacy benefits for federal employee health benefits program, items related to the application of drug benefits to public plans and health exchange, including PBM disclosure in H.R. 3200, S11679 America's Health Future Act, issues related to generic dispensing and study of the impact of state 'carve-out" laws on generic utilization. H.R. 4199 - Patients Health and Real Medication Access Cost Savings Act. H.R. 5234 - PBM Audit Reform and Transparency Act H.R. 4872 - Health Care and Education and Reconciliation Act of 2010 H.R. 4813 - To provide for insurance reform (including health insurance reform) amend Title XVIII of the Social Security Act to reform Medicare Advantage and reduce disparities in the Medicare Program, regulate the importation of prescription drugs, and for other purposes. H.R. 4489 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 3950 - Patient Protection and Affordable Care Act

Client expense: $525,828 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Election Commission (FEC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S 1796, S 1679, HR 3962, HR 3590 (Health Care Reform). HR 1204 (Antitrust exemption for pharmacists) HR 1493 (Antitrust exemption for physicians) HR 1 (COBRA coverage subsidy; comparative effectiveness, wellness, HIT). HR 1427/S 726/ HR 1548 (FDA PAthway to approve generic Biopharmaceutical medicines). S. 369/HR 1706 (Generic/brand settlements). S. 93 (establish FEHBP for small employers) S. 391/H.R. 1321 (National health) H.R. 676/S. 703 (single payer); PL 111-148; PL 111-152.

Client expense: $1,641,400 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Patent Reform, Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate

Client expense: $795,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Patent Reform; Patent Settlements; H.R. 1706 and S. 5369

Client expense: $432,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent reform; Patent settlements; H.R. 1706 and S. 5369

Client expense: $984,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1706 Protecting Consumer Access to Generic Drugs Act S 369 Preserve Access to Affordable Generics Act; HR 4899 (sections 4201-4206) regarding drug safety proposal,drug disposal legislation, authorized generics, generic biologics, FDA.

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate

Client expense: $538,940 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1706 Protecting Consumer Access to Generic Drugs Act; S 369 Preserve Access to Affordable Generics Act; HR 4899 (sections 4201-4206) regarding drug safety proposal.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

A bill to prohibit certain patent settlements between brand name drug companies and generic drug companies (S. 369, H.R. 1706).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medical Research Antibiotic Resistance issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Car and Education Reconcilliation Act of 2010 implementation H.R. 6331 Generating Antibiotic Incentives Now Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S.11 To restore the application of the 340B drug discount program to orphan drugs with respect to children's hospitals H.R. 4994 Medicare and Medicaid Extenders Act of 2010; P.L.111-309 (340B provisions) H.R. 5712 The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286 (340B provisions) H.R. 759 Food and Drug Administration Globalization Act of 2009 S.882 The Drug and Device Accountability Act of 2009 H.R. 5740 To provide for the mandatory recall of adulterated or misbranded drugs S.369 Preserve Access to Affordable Generics Act H.R. 1706 Protecting Consumer Access to Generic Drugs Act H.R.573 Fair Prescription Drug Competition Act S.501 Fair Prescription Drug Competition Act Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) H.R. 4213 American Jobs and Closing Tax Loopholds Act of 2010

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Supported efforts to address issues of inequitable conduct, timing of patent challenges, and damages in Patent Reform Act of 2009 (H.R. 1260 & S. 515); patent settlement issues in Protecting Consumer Access to Generic Drugs Act of 2009 (H.R. 1706) and Preserve Access to Affordable Generics Act (S. 369).

Client expense: $680,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; (cont.) H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; H.R. 3590, Patient Protection and Affordable Care Act (Reid) generic biologics; H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch); H.R. 4899, Supplemental Appropriations Act (Obey) generic drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies; and S. 3677, Financial Services and General Government Appropriations Act (Durbin) generic drugs. PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

Client expense: $1,980,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, Social Security Administration (SSA), Treasury, Dept of

Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate

Client expense: $538,940 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.525/H.R.1298/S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009 - Discussed legislation which would create a system of safe importation of prescription drugs from abroad. S.726/H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act - Discussed legislation which would create a pathway for the approval of safe, effective biosimilar and generic biologic drugs. H.R.1706, Protecting Consumer Access to Generic Drugs Act of 2009 - Discussed legislation that would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. S. 369, Preserve Access to Affordable Generics Act - Discussed legislation that would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market,and for other purposes. S.515/H.R.1260/S.610, Patent Reform Act of 2009 - Discussed legislation that would amend federal patent law to rewrite provisions concerning the conditions for patentability. Specifically, AARP weighed in on the inequitable conduct provisions of the legislation. S. 301, Physician Payments Sunshine Act of 2009 - Discussed legislation that would provide for disclosure of gifts given by pharmaceutical and device manufacturers to physicians. S.1315, Federal Food, Drug and Cosmetic Act Amendment/H.R.3777 Drug Price Competition Act - Lobbied to expand the definition of "first applicant" under such Act to allow a generic drug manufacturer that is currently considered an applicant subsequent to a brand-name manufacturer's 180-day exclusivity period to qualify as a first applicant for purposes of filing an abbreviated application for a new drug. Requires such applicant ot submit a substantially complete application that contains and lawfully maintains a certification for such drug. H.R. 3590, Patient Protection and Affordable Care Act - Lobbied in support of and implementation of health care legislation to reform the health care system to provide quality health care and expand access to long-term services and supports. H.R. 4872, Health Care and Education Reconciliation Act - Lobbied in support of and implementation of health care law which makes improvements, such as closing the Part D coverage gap, in the Patient Protection and Affordable Care Act. S. 3606, Agriculture, Rural Development, FDA and related agencies Appropriations Act, FY 2011 - Lobbied for increased funding for the FDA Office of Generic Drugs to reduction of application backlog. H.R. 3081, H.R. 3082, H.J.Res. 105, H.J.Res.101, Continuing Resolution, FY 2011 - Lobbied for funding for FDA Office of Generic Drugs and nutrition assistance. S.3690, the Drug Safety and Accountability Act of 2010 - Requires drug manufacturers to implement quality management plans and document the manufacturing supply chain to ensure the quality and safety of drugs. The bill also would expand FDA authority to recall unsafe drugs, uncluding over the counter drugs, and offers protection to whistle blowers. H.R.5809,would amend the Controlled Substances Act to provide for the take back and safe disposal of controlled substances. The bill provides for an educational effort about proper drug disposal, an EPA report on the same and a GAO report on the effectiveness of disposal programs.

Client expense: $9,120,000 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, Equal Employment Opportunity Commission (EEOC), Federal Communications Commission (FCC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Office of the Vice President of the United States, SENATE, Securities & Exchange Commission (SEC), Social Security Administration (SSA), Transportation, Dept of (DOT), Treasury, Dept of, White House Office

S.525/H.R.1298/S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009 - Discussed legislation which would create a system of safe importation of prescription drugs from abroad. S.726/H.R.1427, Promoting Innovation and Access to Life-Saving Medicine Act - Discussed legislation which would create a pathway for the approval of safe, effective biosimilar and generic biologic drugs. H.R.1706, Protecting Consumer Access to Generic Drugs Act of 2009 - Discussed legislation that would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. S. 369, Preserve Access to Affordable Generics Act - Discussed legislation that would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market,and for other purposes. S.515/H.R.1260/S.610, Patent Reform Act of 2009 - Discussed legislation that would amend federal patent law to rewrite provisions concerning the conditions for patentability. Specifically, AARP weighed in on the inequitable conduct provisions of the legislation. S. 301, Physician Payments Sunshine Act of 2009 - Discussed legislation that would provide for disclosure of gifts given by pharmaceutical and device manufacturers to physicians. S.1315, Federal Food, Drug and Cosmetic Act Amendment/H.R.3777 Drug Price Competition Act - Lobbied to expand the definition of "first applicant" under such Act to allow a generic drug manufacturer that is currently considered an applicant subsequent to a brand-name manufacturer's 180-day exclusivity period to qualify as a first applicant for purposes of filing an abbreviated application for a new drug. Requires such applicant ot submit a substantially complete application that contains and lawfully maintains a certification for such drug. H.R. 3590, Patient Protection and Affordable Care Act - Lobbied in support of and implementation of health care legislation to reform the health care system to provide quality health care and expand access to long-term services and supports. H.R. 4872, Health Care and Education Reconciliation Act - Lobbied in support of and implementation of health care law which makes improvements, such as closing the Part D coverage gap, in the Patient Protection and Affordable Care Act. S. 3606, Agriculture, Rural Development, FDA and related agencies Appropriations Act, FY 2011 - Lobbied for increased funding for the FDA Office of Generic Drugs to reduction of application backlog. H.R. 3081, H.R. 3082, H.J.Res. 105, H.J.Res.101, Continuing Resolution, FY 2011 - Lobbied for funding for FDA Office of Generic Drugs and nutrition assistance. S.3690, the Drug Safety and Accountability Act of 2010 - Requires drug manufacturers to implement quality management plans and document the manufacturing supply chain to ensure the quality and safety of drugs. The bill also would expand FDA authority to recall unsafe drugs, uncluding over the counter drugs, and offers protection to whistle blowers. H.R.5809,would amend the Controlled Substances Act to provide for the take back and safe disposal of controlled substances. The bill provides for an educational effort about proper drug disposal, an EPA report on the same and a GAO report on the effectiveness of disposal programs.

Client expense: $9,120,000 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, Equal Employment Opportunity Commission (EEOC), Federal Communications Commission (FCC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Office of the Vice President of the United States, SENATE, Securities & Exchange Commission (SEC), Social Security Administration (SSA), Transportation, Dept of (DOT), Treasury, Dept of, White House Office

H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 628, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 4954, To amend title 35, United States Code, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings: false patent marking H.R. 5980, Bring Jobs Back to America: Strategic Manufacturing & Job Repatriation Act: publication of patent applications and the economy H.R. 6352, Patent Lawsuit Reform Act of 2010: false patent marking H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 299, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws S. 1315, Drug Price Competition Act of 2009: 180-day exclusivity issues S. 3677, Financial Services and General Government Appropriations Act, 2011: patent settlements International intellectual property policy issues Biopharmaceutical innovation policy issues

Client expense: $4,900,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

S. 515 - Patent Reform Act of 2009 S. 299 - Expert Patent Courts Pilot Program Act, 1/09 S. 369 - Preserve Access to Affordable Generics, 2/09 Patent Settlements H.R. 1260 - Patent Reform Act, 3/09 H.R. 1706 - Protecting Consumer Access to Generics Drug Act, 3/09

Client expense: $2,590,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)

S.369/HR 1706, Preserve Acess to Affordable Generics; HR 759, FDA Globalization Act; S.3690, Drug Safety & Accountability Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; S.3677, the Financial Services & General Government Appropriations Act; HR3082, Continuing Appropriations & Surface Transportation Act.

Client expense: Not reported · Firm income: $180,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.369/HR 1706, Preserve Acess to Affordable Generics; HR 759, FDA Globalization Act; S.3690, Drug Safety & Accountability Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; S.3677, the Financial Services & General Government Appropriations Act; HR3082, Continuing Appropriations & Surface Transportation Act.

Client expense: Not reported · Firm income: $180,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; and Prescription drug advertising.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation concerning patent settlements between brand name and generic pharmaceutical companies including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs; and FY 2011 Financial Services and General Government Appropriations bill.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009

Client expense: $620,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE